Innoviva Inc

inva.com

The filing excerpts provided do not contain sufficient substantive business information about Innoviva Inc (INVA) to produce a SEC-grounded company description. The excerpts consist only of boilerplate SEC cover page language and do not disclose the company's business activities, revenue model, products, customers, geographic footprint, competitors, or financial results. No factual claims about Innoviva can be supported by the provided source material.

Peers: Aclaris Therapeutics Inc AERIE PHARMACEUTICALS INC Amneal Pharmaceuticals Inc Belite Bio Inc Relmada Therapeutics Inc DICE Therapeutics, Inc. Johnson & Johnson REATA PHARMACEUTICALS INC SIGA Technologies Inc

Source: SEC 10-K, filed 2026-02-25

Dive deeper

Financial Snapshot

Revenue

TTM

$420.7M

Gross Margin

TTM

74.1%

Net Income

TTM

$504.3M

Current Assets

2026 Q1

$772.6M

Current Liabilities

2026 Q1

$36.56M

Current Ratio

2026 Q1

2113.42%

Total Assets

2026 Q1

$1.837B

Total Liabilities

2026 Q1

$363.8M

Book Value

2026 Q1

1.473B

Cash

2026 Q1

$603.1M

P/E

TTM

3.255

Free Cash Flow

TTM

$128.5M

Stock Price

Market Cap: $1.6415 Billion